Cargando…
Standardized Data Structures in Rare Diseases: CDISC User Guides for Duchenne Muscular Dystrophy and Huntington’s Disease
Interest in drug development for rare diseases has expanded dramatically since the Orphan Drug Act was passed in 1983, with 40% of new drug approvals in 2019 targeting orphan indications. However, limited quantitative understanding of natural history and disease progression hinders progress and incr...
Autores principales: | Mullin, Ariana P., Corey, Diane, Turner, Emily C., Liwski, Richard, Olson, Daniel, Burton, Jackson, Sivakumaran, Sudhir, Hudson, Lynn D., Romero, Klaus, Stephenson, Diane T., Larkindale, Jane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877853/ https://www.ncbi.nlm.nih.gov/pubmed/32702147 http://dx.doi.org/10.1111/cts.12845 |
Ejemplares similares
-
Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy
por: Lingineni, Karthik, et al.
Publicado: (2022) -
Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017) -
Effective Data Sharing as a Conduit for Advancing Medical Product Development
por: Karpen, Stephen R., et al.
Publicado: (2021) -
Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012) -
Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)